NexCure Raises $19M in Series A Funding to Standardize CAR-T Treatment Delivery

Some problems in healthcare are scientific. Others are logistical. CAR-T therapy sits right at that intersection. The science is wild. Reprogram a patient’s own immune cells to hunt cancer. It sounds like science fiction. The catch is access. Out of roughly 6,100 hospitals in the United States, only about 150–200 actually administer CAR-T. That means a breakthrough therapy exists, but geography, infrastructure, and operational complexity quietly decide who gets through the door.

Enter NexCure with $19M in Series A financing, led by RA Capital Management with participation from Cencora Ventures and Oncology Ventures. Not a vanity round. This is infrastructure capital aimed squarely at a bottleneck the industry has been politely ignoring. NexCure partners with health systems to build and operate outpatient treatment centers designed specifically for advanced therapies like CAR-T and T cell engagers. Think of it less like building another clinic and more like building the operating system for delivering some of the most complex cancer therapies on the planet.

Jennifer Smith, MBA is running point as CEO and Board Member, bringing more than 20 years of healthcare operations experience into a space that desperately needs operational precision. Sophie Papa, MD PhD, Founder and Chief Medical Officer, brings deep expertise in T cell therapy development. Anish More, MBA, Founder and Chief Business Officer, comes from the strategy and investment side of healthcare innovation. And Paul Rothman, MD, Founder and Board Chair, adds the kind of academic medicine gravity that turns ambitious healthcare infrastructure ideas into systems that actually work in the real world.

The NexCure platform pulls together AI powered patient selection, remote monitoring, standardized clinical protocols, and automated care coordination. In plain terms, it reduces the chaos that normally surrounds advanced therapy delivery. CAR-T is powerful medicine, but it demands tight coordination, specialized oversight, and clinical rigor. NexCure is packaging that complexity into a repeatable model so community settings can safely deliver treatments that historically lived inside major academic hospitals.

There is a quiet lesson here for founders watching the healthcare market. Sometimes the biggest opportunity is not inventing a new molecule. It is fixing the pipes that move breakthroughs from lab bench to patient chair. Infrastructure wins when innovation outruns the system designed to deliver it.

NexCure is betting that the future of advanced oncology treatment will not be confined to a handful of elite institutions. If Jennifer Smith, Sophie Papa, Anish More, and Paul Rothman are right, the next era of cell therapy access will not depend on which city a patient lives in. It will depend on whether the right infrastructure shows up where patients already are. And right now, NexCure looks like it intends to build exactly that.